Skip to main content

Advertisement

Table 2 Participant characteristics according to presence of delayed enhancement on cardiac magnetic resonance scanning

From: Assessment of myocardial abnormalities in rheumatoid arthritis using a comprehensive cardiac magnetic resonance approach: a pilot study

Characteristic * Total n= 18 DE present n= 7 DE absent n= 11 P
Female, n (%) 14 (77.8) 7 (100.0) 7 (63.6) 0.12
Age, years 57.4 ± 10.3 61.9 ± 8.6 54.6 ± 10.6 0.13
SBP, mmHg 122 ± 14 119 ± 13 124 ± 14 0.48
DBP, mmHg 76 ± 9 71 ± 7 78 ± 9 0.09
Total cholesterol, mg/dL 179 ± 19 181 ± 19 178 ± 19 0.68
HDL-C, mg/dL 52 ± 9 51 ± 9 53 ± 9 0.56
LDL-C, mg/dL 100 ± 15 105 ± 18 97 ± 13 0.33
Triglycerides, mg/dL 134 ± 21 130 ± 26 137 ± 18 0.54
Ejection fraction (echocardiogram), % 66 ± 6 67 ± 6 66 ± 6 0.71
Any perfusion defects, n (%) ** 2 (11.1) 1 (14.3) 1 (9.1) 1.00
RA duration, years; median (IQR) 2.7 (0.7 to 9.0) 8.8 (2.5 to 10.5) 1.6 (0.6 to 9) 0.26
RA duration < 3 year, n (%) 10 (55.6) 2 (20.0) 8 (80.0) 0.15
RF, n (%) 16 (88.9) 7 (100.0) 9 (81.8) 0.50
Anti-CCP, n (%) 9 (50.0) 2 (28.6) 7 (63.6) 0.34
DAS28; median (IQR) 3.96 ± 1.20 4.77 ± 0.78 3.44 ± 1.16 0.01
CRP, mg/L; median (IQR) 2.61 (1.10 to 4.22) 4.22 (3.08 to 5.28) 1.22 (0.50 to 3.40) 0.08
ESR, mm/hr; median (IQR) 47 (28 to 60) 60 (46 to 68) 39 (28 to 47) 0.09
HAQ (0-3) 0.88 (0.25 to 1.0) 1.0 (0.75 to 1.0) 0.25 (0.25 to 1.0) 0.28
Framingham risk score; median (IQR) 2.0 (0.5 to 4.0) 1.0 (0.5 to 6.0) 2.0 (1.0 to 3.0) 0.75
TNF inhibitor use, n (%) 7 (38.9) 1 (14.3) 6 (54.6) 0.15
  1. * Characteristics are expressed as mean ± standard deviation unless otherwise noted.
  2. ** The two perfusion defects detected represented different processes. The subject with DE demonstrated a perfusion defect pattern consistent with microvascular impairment while the subject without DE demonstrated a perfusion defect pattern consistent with macrovascular impairment.